Clinical Trial Detail

NCT ID NCT02844816
Title Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

bladder urothelial carcinoma

Therapies

Atezolizumab

Age Groups: senior adult

No variant requirements are available.